Servier secures EC approval of LONSURF for treating metastatic gastric cancer
Phase III trial TAGS is designed to evaluate LONSURF in combination with best supportive care (BSC), with placebo…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Sep 19
Phase III trial TAGS is designed to evaluate LONSURF in combination with best supportive care (BSC), with placebo…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
27 Aug 19
The closing of the transaction is subject to the signing of a consent decree by Bristol-Myers Squibb and…
21 Aug 19
The FDA acceptance is based on the previously announced positive results of two global Phase 3 studies in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates